---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-25-000003"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:42:29.021502+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics reports preliminary Q4 2024 revenue of $165M, down 10% YoY but up 9% sequentially

## Summary
- FY2024 revenue ~$610.8M (-1% YoY); Q4 revenue ~$165M (-10% YoY, +9% sequentially).
- Instruments Q4 revenue $24.4M (-37% YoY); consumables $133.5M (-5% YoY); services $7.1M (+35% YoY).
- Cumulative instruments deployed >7,000; cash and equivalents ~$393M.
- Preliminary and unaudited; subject to adjustment after year-end close.

## SEC filing metadata
- accession: 0001770787-25-000003
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000003/0001770787-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078725000003/txg-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-25-000003
- JSON: https://secwatch.observer/filing/0001770787-25-000003.json
- Plain text: https://secwatch.observer/filing/0001770787-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.